Wedbush Issues Optimistic Estimate for PTGX Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Analysts at Wedbush increased their Q3 2025 earnings per share estimates for Protagonist Therapeutics in a research report issued to clients and investors on Thursday, August 7th. Wedbush analyst Y. Zhong now expects that the company will post earnings per share of ($0.57) for the quarter, up from their previous estimate of ($0.62). The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. Wedbush also issued estimates for Protagonist Therapeutics’ Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($1.91) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($0.35) EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.02). Protagonist Therapeutics had a return on equity of 8.12% and a net margin of 24.88%. The firm had revenue of $5.55 million for the quarter, compared to analysts’ expectations of $8.32 million.

Other equities analysts have also issued research reports about the company. Citigroup reissued an “outperform” rating on shares of Protagonist Therapeutics in a report on Thursday. JMP Securities lifted their price objective on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a report on Thursday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. Finally, Wall Street Zen raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, June 8th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.20.

Protagonist Therapeutics Stock Up 5.2%

NASDAQ PTGX opened at $53.75 on Monday. Protagonist Therapeutics has a 52-week low of $33.31 and a 52-week high of $60.60. The business’s 50-day moving average price is $53.88 and its 200 day moving average price is $47.54. The firm has a market cap of $3.34 billion, a P/E ratio of 76.79 and a beta of 2.33.

Insider Activity at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 22,065 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, July 22nd. The stock was sold at an average price of $55.05, for a total transaction of $1,214,678.25. Following the completion of the transaction, the chief executive officer directly owned 548,538 shares in the company, valued at $30,197,016.90. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Arturo Md Molina sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total value of $570,300.00. Following the completion of the transaction, the insider owned 83,892 shares of the company’s stock, valued at $4,784,360.76. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,859 shares of company stock valued at $4,020,877 over the last 90 days. Insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Farallon Capital Management LLC raised its holdings in Protagonist Therapeutics by 1.2% in the 4th quarter. Farallon Capital Management LLC now owns 5,930,006 shares of the company’s stock valued at $228,898,000 after acquiring an additional 69,000 shares during the last quarter. RTW Investments LP raised its holdings in Protagonist Therapeutics by 1.3% in the 4th quarter. RTW Investments LP now owns 5,498,545 shares of the company’s stock valued at $212,244,000 after acquiring an additional 72,433 shares during the last quarter. Vanguard Group Inc. raised its holdings in Protagonist Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 4,277,218 shares of the company’s stock valued at $206,846,000 after acquiring an additional 57,181 shares during the last quarter. BVF Inc. IL raised its holdings in Protagonist Therapeutics by 35.5% in the 1st quarter. BVF Inc. IL now owns 2,575,015 shares of the company’s stock valued at $124,528,000 after acquiring an additional 675,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Protagonist Therapeutics by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,444,230 shares of the company’s stock valued at $79,833,000 after acquiring an additional 20,671 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.